CLAIMS

1. A CD106 positive kidney derived fibroblast having enhanced erythropoietin (EPO) productivity, wherein EPO production of the fibroblast is not less than 1.65 times higher than in a CD106 negative kidney derived fibroblast as a control.

~~2. The fibroblast according to claim 1, which is positive for CD106.~~

~~3. The fibroblast according to claim 1 or 2, wherein the fibroblast is a kidney fibroblast.~~

~~4. The fibroblast according to any one of claims 1 to 3, wherein the EPO production is not less than 1.65 times higher than in a control fibroblast.~~

~~5~~2. A cell population of fibroblast comprising the fibroblast according to ~~any one of~~ claim~~s~~ 1 ~~to 4~~.

~~6~~3. The cell population according to claim ~~5~~2, wherein the ratio of the CD106-positive fibroblast (in terms of the cell number) is not less than 4.7% relative to the total fibroblasts contained in the cell population.

~~7~~4. A method of producing kidney derived fibroblasts having enhanced EPO productivity, the method comprising:

bringing kidney derived fibroblasts into contact with TNF-α and IL-4; and

culturing, under conditions allowing enhancement of EPO productivity, the fibroblasts that have been brought into contact, wherein EPO production of the fibroblast is not less than 1.65 times higher than in a control fibroblast.

~~8~~5. The method according to claim ~~7~~4, wherein the kidney derived fibroblasts having enhanced EPO productivity are positive for CD106.

~~9~~6. The method according to claim ~~8~~5, further comprising selecting or concentrating CD106-positive fibroblasts using an anti-CD106 antibody.

~~10. The method according to any one of claims 7 to 9, wherein the fibroblasts are kidney fibroblasts.~~

~~11. A fibroblast having enhanced EPO productivity, obtained by the production method according to any one of claims 7 to 10.~~

~~12. A cell population of fibroblast comprising the fibroblast according to claim 11.~~

~~13~~7. A pharmaceutical composition comprising~~:~~ the fibroblast according to ~~any one of~~ claim 1~~s 1 to 4 and 11;~~ or the cell population according to any ~~one~~ of claims ~~5, 6, and 12~~2 or 3.

~~14~~8. Use of the fibroblast of claim 1, the cell population of any of claims 2 or 3, or the pharmaceutical composition of claim 7 in the manufacture of a medicament ~~The pharmaceutical composition according to claim 13,~~ for improvement of a state where EPO productivity is decreased.

~~15~~9. Use of the fibroblast of claim 1, the cell population of any of claims 2 or 3, or the pharmaceutical composition of claim 7 in the manufacture of a medicament~~The pharmaceutical composition according to claim 13,~~ for ~~administration to~~ the treatment of a ~~patient having a~~ renal disorder.

~~16~~10. The ~~pharmaceutical composition according to~~use according to claim ~~15~~9, wherein the renal disorder is chronic kidney disease.

~~17~~11. Use of the fibroblast of claim 1, the cell population of any of claims 2 or 3, or the pharmaceutical composition of claim 7 in the manufacture of a medicament~~The pharmaceutical composition according to claim 13,~~ for ~~administration to~~ the treatment of ~~a patient having~~ renal anemia.

~~18~~12. The ~~pharmaceutical composition~~ use according to any one of claims ~~13~~ 8 to ~~17~~11, ~~which is an~~wherein the medicament is an injectable composition.

~~19~~13. The pharmaceutical composition according to claim 7 or the use according to any one of claims ~~13~~ 8 to ~~17~~11, wherein the cell population is constructed as a planar or three-dimensional cellular tissue.

14. The fibroblast of claim 1, the cell population of any of claims 2 or 3, or the pharmaceutical composition of claim 7 for use in therapy.